Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer

Journal of Translational Medicine

Zhen Chen¹  Lian-Yu Chen¹  Lu-Ming Liu¹  Ke Zhang¹  Cai-Jun Wu¹  Hao Chen¹  Yong-Qiang Hua¹  Dan Wang¹ 

[1] Department of Integrative Oncology, Fudan University Shanghai Cancer Center;

关键词: Pancreatic cancer;    Prognostic marker;    Systemic immune-inflammation index;    CA19-9;   

DOI  :  10.1186/s12967-019-1782-x

来源: DOAJ

【 摘 要 】

Abstract Background Systemic inflammation and immune dysfunction have been proved to be associated with cancer progression and metastasis in various malignancies. The aim of this retrospective study was to evaluate the prognostic significance of pre-treatment systemic immune-inflammation index (SII) in patients with advanced pancreatic cancer. Methods In total, 419 patients diagnosed with advanced pancreatic cancer, between January 2011 and December 2015, were retrospectively enrolled. The SII was developed based on a training set of 197 patients from 2011 to 2013 and validated in an independent cohort of 222 patients from 2014 to 2015. Data on baseline clinicopathologic characteristics; pre-treatment laboratory variables such as absolute neutrophil, lymphocyte, and platelet counts; and carbohydrate antigen 19-9 (CA19-9), total bilirubin (TBIL), albumin (ALB), alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate transaminase (AST) levels were collected. The association between clinicopathologic characteristics and SII was assessed. The overall survival was calculated using the Kaplan–Meier survival curves and compared using the log-rank test. Univariate and multivariate Cox proportional hazard regression models were used to analyze the prognostic value of the SII. Result An optimal cutoff point for the SII of 440 stratified the patients with advanced pancreatic cancer into high (> 440) and low (≤ 440) SII groups in the training cohort. Univariate and multivariate analyses revealed that the SII was an independent predictor for overall survival. The prognostic significance of the SII was confirmed in both normal and elevated CA19-9 levels. Conclusion The baseline SII serves as an independent prognostic marker for patients with advanced pancreatic cancer and can be used in patients with both normal and elevated CA19-9 levels.

【 授权许可】

Unknown